Inicio › Cáncer de pulmón de células no pequeñas › Oregón

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Oregón

62 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Oregón.

Ciudades en Oregón

Texto oficial del estudio (inglés)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Providence Cancer Institute Franz Clinic, Portland
Providence St. Vincent Medical Center, Portland
Oregon Health and Science University, Portland

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07100080

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

St. Charles Health System, Inc ( Site 0146), Bend

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Providence Hood River Memorial Hospital, Hood River
Providence Newberg Medical Center, Newberg
Providence Willamette Falls Medical Center, Oregon City
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Good Samaritan Hospital, Corvallis
Three Rivers Community Hospital, Grants Pass
Asante Rogue Regional Medical Center, Medford
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Oregon Health and Science University ( Site 0052), Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06312137

A Study of DS-3939a in Participants With Solid Tumors

Oregon Health & Science University, Portland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07739966

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Local Institution - 0404, Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07680790

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217), Corvallis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06623422

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

OHSU Knight Cancer Institute, Beaverton, Beaverton
Oncology Associates of Oregon, P.C., Eugene
OHSU Knight Cancer Institute, Gresham, Gresham
y 10 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07144280

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Oregon Health and Science University, Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06793215

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Oncology Associates Of Oregon, Pc, Eugene
Northwest Cancer Specialists, P.C., Happy Valley

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07361497

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Providence Portland Medical Center, Portland
Providence St. Vincent Medical Center, Portland
Kaiser Permanente Interstate Medical Office Central, Portland
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06890598

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR Oncology Associates of Oregon, P.C., Eugene
Compass Oncology - Rose Quarter, Portland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Saint Alphonsus Cancer Care Center-Baker City, Baker City
Saint Alphonsus Cancer Care Center-Ontario, Ontario
Kaiser Permanente Northwest, Portland

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

USO - Oncology Associates of Oregon, Eugene
Asante Rogue Regional Medical Center, Medford
Providence Portland Medical Center, Portland
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

OHSU Knight Cancer Institute, Portland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07397338

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Providence Cancer Center, Portland
Providence Oncology and Hematology Care Clinic Westside, Portland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07586202

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Saint Alphonsus Cancer Care Center-Baker City, Baker City
Good Samaritan Hospital, Corvallis
Saint Alphonsus Cancer Care Center-Ontario, Ontario

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT03191149

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

Providence Cancer Institute, Portland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07542704

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Asante Rogue Region al Medical Center, Medford

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06303505

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Clackamas Radiation Oncology Center, Clackamas
Providence Newberg Medical Center, Newberg
Providence Willamette Falls Medical Center, Oregon City
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07293247

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117), Corvallis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06170788

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Oregon Health And Science University, Portland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06667908

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Williamette Valley Cancer Institute and Research Center, Eugene
Providence Portland Medical Center, Portland
Providence Oncology & Hematology Care Clinic - Westside, West Haven-Sylvan

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07288177

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Providence Cancer Institute, Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
Local Institution - 007-885B, Portland
Local Institution - 007-885A, Portland
y 2 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT04613596

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA15-0, Portland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06953089

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Providence Cancer Institute, Portland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT05098132

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Medford
Research Site, Salem

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06692738

A Study of MGC026 in Participants With Advanced Solid Tumors

Providence Cancer Institute, Portland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06242470

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

St. Charles Health System, Bend

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06899126

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Oregon Health and Science University, Portland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07154290

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute, Portland

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT07405086

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Oregon Health & Science University, Portland

ReclutandoFase 3

Edades de 18 a 100 · Todos los sexos · Actualizado el 13 oct 2026 · NCT05317858

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Saint Alphonsus Cancer Care Center-Ontario, Ontario
Kaiser Permanente Northwest, Portland
Oregon Health and Science University, Portland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Saint Alphonsus Cancer Care Center-Ontario, Ontario
Kaiser Permanente Northwest, Portland

ReclutandoFase 2

18 Minutes · Todos los sexos · Actualizado el 9 oct 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Saint Alphonsus Cancer Care Center-Baker City, Baker City
Saint Alphonsus Cancer Care Center-Ontario, Ontario
Kaiser Permanente Northwest, Portland
y 1 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT06616584

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Northwest Cancer Specialists, P.C, Happy Valley
Northwest Cancer Specialists, P.C., Portland
Northwest Cancer Specialists, P.C, Tigard

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07222566

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Oncology Associates of Oregon, P.C., Eugene

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07227298

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Oregon Health & Science University (OHSU), Portland

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.